{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:25:42Z","timestamp":1792074342802,"version":"4.4.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s43440-025-00739-0","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T02:07:55Z","timestamp":1748484475000},"page":"1177-1195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Marizomib in the therapy of brain tumors\u2014how far did we go and where do we stand?"],"prefix":"10.1007","volume":"77","author":[{"given":"Magdalena","family":"Kusaczuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria Monika","family":"Piskorz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Domasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"739_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2217\/nnm-2021-0034","volume":"16","author":"LE Ibarra","year":"2021","unstructured":"Ibarra LE. Cellular Trojan horses for delivery of nanomedicines to brain tumors: where do we stand and what is next? Nanomed (Lond). 2021;16:517\u201322. https:\/\/doi.org\/10.2217\/nnm-2021-0034.","journal-title":"Nanomed (Lond)"},{"key":"739_CR2","doi-asserted-by":"publisher","first-page":"189054","DOI":"10.1016\/j.bbcan.2023.189054","volume":"1879","author":"M Kusaczuk","year":"2024","unstructured":"Kusaczuk M, Ambel ET, Naumowicz M, Velasco G. Cellular stress responses as modulators of drug cytotoxicity in pharmacotherapy of glioblastoma. Biochim Biophys Acta Rev Cancer. 2024;1879:189054. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189054.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"739_CR3","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2174\/1381612821666150105160059","volume":"21","author":"M Kusaczuk","year":"2015","unstructured":"Kusaczuk M, Bartoszewicz M, Cechowska-Pasko M. Phenylbutyric acid: simple structure - multiple effects. Curr Pharm Des. 2015;21:2147\u201366. https:\/\/doi.org\/10.2174\/1381612821666150105160059.","journal-title":"Curr Pharm Des"},{"key":"739_CR4","first-page":"3937","volume":"6","author":"H Kato","year":"2000","unstructured":"Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Kato S, et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res. 2000;6:3937\u201343.","journal-title":"Clin Cancer Res"},{"key":"739_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/1541-7786.MCR-08-0270","volume":"7","author":"D Yin","year":"2009","unstructured":"Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, Eoli M, et al. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide poly-morphism DNA microarray. Mol Cancer Res. 2009;7:665\u201377. https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0270.","journal-title":"Mol Cancer Res"},{"key":"739_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/13543784.2020.1803827","volume":"29","author":"P Roth","year":"2020","unstructured":"Roth P, Mason WP, Richardson PG, Weller M. Proteasome Inhibition for the treatment of glioblastoma. Expert Opin Investig Drugs. 2020;29:1133\u201341. https:\/\/doi.org\/10.1080\/13543784.2020.1803827.","journal-title":"Expert Opin Investig Drugs"},{"key":"739_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/ijms23031345","volume":"23","author":"M Kusaczuk","year":"2022","unstructured":"Kusaczuk M, Kretowski R, Naumowicz M, Stypu\u0142kowska A, Cechowska-Pasko M. A preliminary study of the effect of Quercetin on cytotoxicity, apoptosis, and stress responses in glioblastoma cell lines. Int J Mol Sci. 2022;23:1345. https:\/\/doi.org\/10.3390\/ijms23031345.","journal-title":"Int J Mol Sci"},{"key":"739_CR8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: A review. JAMA. 2023;329:574\u201387. https:\/\/doi.org\/10.1001\/jama.2023.0023.","journal-title":"JAMA"},{"key":"739_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.22.00164","volume":"41","author":"CI Tsien","year":"2023","unstructured":"Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, et al. NRG Oncology\/RTOG1205: A randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol. 2023;41:1285\u201395. https:\/\/doi.org\/10.1200\/JCO.22.00164.","journal-title":"J Clin Oncol"},{"key":"739_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/b:neon.0000013479.64348.69","volume":"66","author":"A Silvani","year":"2004","unstructured":"Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G, et al. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol. 2004;66:203\u20138. https:\/\/doi.org\/10.1023\/b:neon.0000013479.64348.69.","journal-title":"J Neurooncol"},{"key":"739_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15:943\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(14)70314-6.","journal-title":"Lancet Oncol"},{"key":"739_CR12","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377:1954\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1707358.","journal-title":"N Engl J Med"},{"key":"739_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/neuonc\/nov126","volume":"17","author":"J Pallud","year":"2015","unstructured":"Pallud J, Audureau E, Noel G, Corns R, Lechapt-Zalcman E, Duntze J, et al. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. Neuro Oncol. 2015;17:1609\u201319. https:\/\/doi.org\/10.1093\/neuonc\/nov126.","journal-title":"Neuro Oncol"},{"key":"739_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/pr.117.014944","volume":"70","author":"A Shergalis","year":"2018","unstructured":"Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N. Current challenges and opportunities in treating glioblastoma. Pharmacol Rev. 2018;70:412\u201345. https:\/\/doi.org\/10.1124\/pr.117.014944.","journal-title":"Pharmacol Rev"},{"key":"739_CR15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","volume":"87","author":"JAM Bard","year":"2018","unstructured":"Bard JAM, Goodall EA, Greene ER, Jonsson E, Dong KC, Martin A. Structure and function of the 26S proteasome. Annu Rev Biochem. 2018;87:697\u2013724. https:\/\/doi.org\/10.1146\/annurev-biochem-062917-011931.","journal-title":"Annu Rev Biochem"},{"key":"739_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/sj.leu.2402417","volume":"16","author":"J Almond","year":"2002","unstructured":"Almond J, Cohen G. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002;16:433\u201343. https:\/\/doi.org\/10.1038\/sj.leu.2402417.","journal-title":"Leukemia"},{"key":"739_CR17","doi-asserted-by":"publisher","first-page":"107579","DOI":"10.1016\/j.pharmthera.2020.107579","volume":"213","author":"GR Tundo","year":"2020","unstructured":"Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, et al. The proteasome as a druggable target with multiple therapeutic potentialities: cutting and non-cutting edges. Pharmacol Ther. 2020;213:107579. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107579.","journal-title":"Pharmacol Ther"},{"key":"739_CR18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947\u201359. https:\/\/doi.org\/10.1182\/blood-2012-04-403733.","journal-title":"Blood"},{"issue":"6","key":"739_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","volume":"44","author":"AT Nunes","year":"2017","unstructured":"Nunes AT, Annunziata CM. Proteasome inhibitors: structure and function. Semin Oncol. 2017;44(6):377\u201380. https:\/\/doi.org\/10.1053\/j.seminoncol.2018.01.004.","journal-title":"Semin Oncol"},{"key":"739_CR20","doi-asserted-by":"publisher","first-page":"123125","DOI":"10.1016\/j.lfs.2024.123125","volume":"358","author":"O Sogbein","year":"2024","unstructured":"Sogbein O, Paul P, Umar M, Chaari A, Batuman V, Upadhyay R. Bortezomib in cancer therapy: mechanisms, side effects, and future proteasome inhibitors. Life Sci. 2024;358:123125. https:\/\/doi.org\/10.1016\/j.lfs.2024.123125.","journal-title":"Life Sci"},{"key":"739_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.04.008","volume":"96","author":"BA Teicher","year":"2015","unstructured":"Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochem Pharmacol. 2015;96:1\u20139. https:\/\/doi.org\/10.1016\/j.bcp.2015.04.008.","journal-title":"Biochem Pharmacol"},{"key":"739_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","volume":"14","author":"EE Manasanch","year":"2017","unstructured":"Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14:417\u201333. https:\/\/doi.org\/10.1038\/nrclinonc.2016.206.","journal-title":"Nat Rev Clin Oncol"},{"key":"739_CR23","doi-asserted-by":"publisher","first-page":"CD010816","DOI":"10.1002\/14651858.CD010816.pub2","volume":"4","author":"K Scott","year":"2016","unstructured":"Scott K, Hayden PJ, Will A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016;4:CD010816. https:\/\/doi.org\/10.1002\/14651858.CD010816.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"739_CR24","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.2217\/fon.15.191","volume":"11","author":"T Robak","year":"2015","unstructured":"Robak T. Bortezomib in the treatment of mantle cell lymphoma. Future Oncol. 2015;11:2807\u201318. https:\/\/doi.org\/10.2217\/fon.15.191.","journal-title":"Future Oncol"},{"key":"739_CR25","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1039\/d3bm00254c","volume":"11","author":"J Liu","year":"2023","unstructured":"Liu J, Xu X, Li Y, Xu J, Zhao R, Liu S, et al. Bortezomib-loaded mixed micelles realize a three-in-one effect for enhanced breast cancer treatment. Biomater Sci. 2023;11:4890\u2013906. https:\/\/doi.org\/10.1039\/d3bm00254c.","journal-title":"Biomater Sci"},{"issue":"Suppl 2","key":"739_CR26","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.3816\/clc.2005.s.008","volume":"7","author":"DP Schenkein","year":"2005","unstructured":"Schenkein DP. Preclinical data with bortezomib in lung cancer. Clin Lung Cancer. 2005;7(Suppl 2):S49\u201355. https:\/\/doi.org\/10.3816\/clc.2005.s.008.","journal-title":"Clin Lung Cancer"},{"key":"739_CR27","doi-asserted-by":"publisher","unstructured":"Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70:3853. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2766. Erratum in: Cancer Res. 2010;70:3853. Hales, Paul [added].","DOI":"10.1158\/0008-5472.CAN-09-2766"},{"key":"739_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.intimp.2011.11.019","volume":"12","author":"MM Seavey","year":"2012","unstructured":"Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA. Novel, orally active, proteasome inhibitor, Delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012;12:257\u201370. https:\/\/doi.org\/10.1016\/j.intimp.2011.11.019.","journal-title":"Int Immunopharmacol"},{"key":"739_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.htct.2018.07.003","volume":"41","author":"VTM Hungria","year":"2019","unstructured":"Hungria VTM, Cruso\u00e9 EQ, Bittencourt RI, Maiolino A, Magalh\u00e3es RJP, Sobrinho JDN, et al. New proteasome inhibitors in the treatment of multiple myeloma. Hematol Transfus Cell Ther. 2019;41:76\u201383. https:\/\/doi.org\/10.1016\/j.htct.2018.07.003.","journal-title":"Hematol Transfus Cell Ther"},{"key":"739_CR30","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1038\/s41598-020-62088-7","volume":"10","author":"JL Rausch","year":"2020","unstructured":"Rausch JL, Ali AA, Lee DM, Gebreyohannes YK, Mehalek KR, Agha A, et al. Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in Gastrointestinal stromal tumor (GIST) cells. Sci Rep. 2020;10:5178. https:\/\/doi.org\/10.1038\/s41598-020-62088-7.","journal-title":"Sci Rep"},{"key":"739_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41420-024-01819-5","volume":"10","author":"P Larsson","year":"2024","unstructured":"Larsson P, Pettersson D, Olsson M, Sarathchandra S, Abramsson A, Zetterberg H, et al. Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer. Cell Death Discov. 2024;10:57. https:\/\/doi.org\/10.1038\/s41420-024-01819-5.","journal-title":"Cell Death Discov"},{"key":"739_CR32","first-page":"2875","volume":"12","author":"J Li","year":"2020","unstructured":"Li J, Zhuo JY, Zhou W, Hong JW, Chen RG, Xie HY, et al. Endoplasmic reticulum stress triggers delanzomib-induced apoptosis in HCC cells through the PERK\/eIF2\u03b1\/ATF4\/CHOP pathway. Am J Transl Res. 2020;12:2875\u201389.","journal-title":"Am J Transl Res"},{"key":"739_CR33","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1021\/mp2004143","volume":"9","author":"CR Berkers","year":"2012","unstructured":"Berkers CR, Leestemaker Y, Schuurman KG, Ruggeri B, Jones-Bolin S, Williams M, et al. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and Delanzomib. Mol Pharm. 2012;9:1126\u201335. https:\/\/doi.org\/10.1021\/mp2004143.","journal-title":"Mol Pharm"},{"key":"739_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1080\/15384047.2018.1529095","volume":"20","author":"D Yue","year":"2019","unstructured":"Yue D, Sun X. Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells. Cancer Biol Ther. 2019;20:284\u201394. https:\/\/doi.org\/10.1080\/15384047.2018.1529095.","journal-title":"Cancer Biol Ther"},{"key":"739_CR35","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, \u0160pi\u010dka I, Quach H, Oriol A, H\u00e1jek R, Garg M et al. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial [correction in J Clin Oncol. 2022;40:919. doi:10.1200\/JCO.20.02060].https:\/\/doi.org\/10.1200\/JCO.22.00210]. J Clin Oncol. 2020;38:4030\u20134041.","DOI":"10.1200\/JCO.22.00210]"},{"key":"739_CR36","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","volume":"116","author":"D Chauhan","year":"2010","unstructured":"Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010;116:4906\u201315. https:\/\/doi.org\/10.1182\/blood-2010-04-276626.","journal-title":"Blood"},{"key":"739_CR37","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-12-1213","volume":"18","author":"Y Zang","year":"2012","unstructured":"Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, et al. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res. 2012;18:5639\u201349. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1213.","journal-title":"Clin Cancer Res"},{"key":"739_CR38","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"DJ Kuhn","year":"2007","unstructured":"Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of Carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281\u201390. https:\/\/doi.org\/10.1182\/blood-2007-01-065888.","journal-title":"Blood"},{"key":"739_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s10637-016-0327-x","volume":"34","author":"JR Infante","year":"2016","unstructured":"Infante JR, Mendelson DS, Burris HA 3rd, Bendell JC, Tolcher AW, Gordon MS, et al. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Invest New Drugs. 2016;34:216\u201324. https:\/\/doi.org\/10.1007\/s10637-016-0327-x.","journal-title":"Invest New Drugs"},{"key":"739_CR40","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1878-0261.13595","volume":"18","author":"F Maione","year":"2024","unstructured":"Maione F, Oddo D, Galvagno F, Falcomat\u00e0 C, Pandini M, Macagno M, et al. Preclinical efficacy of Carfilzomib in BRAF-mutant colorectal cancer models. Mol Oncol. 2024;18:1552\u201370. https:\/\/doi.org\/10.1002\/1878-0261.13595.","journal-title":"Mol Oncol"},{"key":"739_CR41","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41416-024-02774-9","volume":"131","author":"A Besse","year":"2024","unstructured":"Besse A, Sedlarikova L, Buechler L, Kraus M, Yang CH, Strakova N, et al. HIV-protease inhibitors potentiate the activity of Carfilzomib in triple-negative breast cancer. Br J Cancer. 2024;131:918\u201330. https:\/\/doi.org\/10.1038\/s41416-024-02774-9.","journal-title":"Br J Cancer"},{"key":"739_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jconrel.2019.04.006","volume":"302","author":"JE Park","year":"2019","unstructured":"Park JE, Park J, Jun Y, Oh Y, Ryoo G, Jeong YS, et al. Expanding therapeutic utility of Carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. J Control Release. 2019;302:148\u201359. https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.006.","journal-title":"J Control Release"},{"key":"739_CR43","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial [correction in Lancet Oncol. 2017;18:e562. doi: 10.1016\/S1470-2045(17)30721-0]. Lancet Oncol. 2017;18:1327\u20131337. https:\/\/doi.org\/10.1016\/S1470-2045(17)30578-8","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"739_CR44","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly Carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study [published correction appears in lancet oncol. 2018;19(8):e382. doi:10.1016\/S1470-2045(18)30492-3]. Lancet Oncol. 2018;19:953\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(18)30354-1.","journal-title":"Lancet Oncol"},{"key":"739_CR45","doi-asserted-by":"publisher","first-page":"34988","DOI":"10.18632\/oncotarget.9222","volume":"7","author":"YP Vandewynckel","year":"2016","unstructured":"Vandewynckel YP, Coucke C, Laukens D, Devisscher L, Paridaens A, Bogaerts E, et al. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma. Oncotarget. 2016;7:34988\u20135000. https:\/\/doi.org\/10.18632\/oncotarget.9222.","journal-title":"Oncotarget"},{"key":"739_CR46","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/abbs\/gmz093","volume":"51","author":"H Zhu","year":"2019","unstructured":"Zhu H, Wang T, Xin Z, Zhan Y, Gu G, Li X, et al. An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro. Acta Biochim Biophys Sin (Shanghai). 2019;51:1034\u201340. https:\/\/doi.org\/10.1093\/abbs\/gmz093.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"739_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41408-019-0232-6","volume":"9","author":"P Hari","year":"2019","unstructured":"Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, et al. Oprozomib in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2019;9:66. https:\/\/doi.org\/10.1038\/s41408-019-0232-6.","journal-title":"Blood Cancer J"},{"key":"739_CR48","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1158\/1078-0432.CCR-18-3728","volume":"25","author":"IM Ghobrial","year":"2019","unstructured":"Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, et al. A phase Ib\/II study of oprozomib in patients with advanced multiple myeloma and Waldenstr\u00f6m macroglobulinemia. Clin Cancer Res. 2019;25:4907\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3728.","journal-title":"Clin Cancer Res"},{"key":"739_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.leukres.2017.03.002","volume":"57","author":"E Sanchez","year":"2017","unstructured":"Sanchez E, Li M, Wang CS, Tang G, Gillespie A, Chen H, et al. Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with Pomalidomide (Pom) and\/or dexamethasone (Dex). Leuk Res. 2017;57:45\u201354. https:\/\/doi.org\/10.1016\/j.leukres.2017.03.002.","journal-title":"Leuk Res"},{"key":"739_CR50","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-15-2616","volume":"22","author":"SJ Harrison","year":"2016","unstructured":"Harrison SJ, Mainwaring P, Price T, Millward MJ, Padrik P, Underhill CR, et al. Phase I clinical trial of Marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 final results. Clin Cancer Res. 2016;22:4559\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2616.","journal-title":"Clin Cancer Res"},{"key":"739_CR51","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3390\/ph17081089","volume":"17","author":"M Kusaczuk","year":"2024","unstructured":"Kusaczuk M, Tyszka N, Kr\u0119towski R, Cechowska-Pasko M. The proteasome inhibitor Marizomib evokes Endoplasmic reticulum stress and promotes apoptosis in human glioblastoma cells. Pharmaceuticals (Basel). 2024;17:1089. https:\/\/doi.org\/10.3390\/ph17081089.","journal-title":"Pharmaceuticals (Basel)"},{"key":"739_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1349-7006.2007.00638.x","volume":"99","author":"Y Ogawa","year":"2008","unstructured":"Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, et al. Phase I and II Pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci. 2008;99:140\u20134. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00638.x.","journal-title":"Cancer Sci"},{"key":"739_CR53","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","volume":"124","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor Ixazomib in relapsed\/refractory multiple myeloma. Blood. 2014;124:1047\u201355. https:\/\/doi.org\/10.1182\/blood-2014-01-548941.","journal-title":"Blood"},{"key":"739_CR54","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","volume":"124","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, et al. Phase 1 study of twice-weekly Ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients. Blood. 2014;124:1038\u201346. https:\/\/doi.org\/10.1182\/blood-2014-01-548826.","journal-title":"Blood"},{"key":"739_CR55","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ejca.2012.09.009","volume":"49","author":"E Gallerani","year":"2013","unstructured":"Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, et al. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer. 2013;49:290\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2012.09.009.","journal-title":"Eur J Cancer"},{"key":"739_CR56","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1124\/dmd.111.039164","volume":"39","author":"J Yang","year":"2011","unstructured":"Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of Carfilzomib in rats. Drug Metab Dispos. 2011;39:1873\u201382. https:\/\/doi.org\/10.1124\/dmd.111.039164.","journal-title":"Drug Metab Dispos"},{"key":"739_CR57","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1124\/dmd.117.075226","volume":"45","author":"Z Wang","year":"2017","unstructured":"Wang Z, Fang Y, Teague J, Wong H, Morisseau C, Hammock BD, et al. In vitro metabolism of oprozomib, an oral proteasome inhibitor: role of epoxide hydrolases and cytochrome P450s. Drug Metab Dispos. 2017;45:712\u201320. https:\/\/doi.org\/10.1124\/dmd.117.075226.","journal-title":"Drug Metab Dispos"},{"key":"739_CR58","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.bbrc.2012.11.137","volume":"430","author":"S Shimizu","year":"2013","unstructured":"Shimizu S, Kadowaki M, Yoshioka H, Kambe A, Watanabe T, Kinyamu HK, et al. Proteasome inhibitor MG132 induces NAG-1\/GDF15 expression through the p38 MAPK pathway in glioblastoma cells. Biochem Biophys Res Commun. 2013;430:1277\u201382. https:\/\/doi.org\/10.1016\/j.bbrc.2012.11.137.","journal-title":"Biochem Biophys Res Commun"},{"key":"739_CR59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11060-016-2156-3","volume":"129","author":"JJ Raizer","year":"2016","unstructured":"Raizer JJ, Chandler JP, Ferrarese R, Grimm SA, Levy RM, Muro K, et al. A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. J Neurooncol. 2016;129:139\u201346. https:\/\/doi.org\/10.1007\/s11060-016-2156-3.","journal-title":"J Neurooncol"},{"key":"739_CR60","doi-asserted-by":"publisher","first-page":"vdab142","DOI":"10.1093\/noajnl\/vdab142","volume":"3","author":"DA Bota","year":"2021","unstructured":"Bota DA, Mason W, Kesari S, Magge R, Winograd B, Elias I, et al. Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: phase I\/II clinical trial data. Neurooncol Adv. 2021;3:vdab142. https:\/\/doi.org\/10.1093\/noajnl\/vdab142.","journal-title":"Neurooncol Adv"},{"key":"739_CR61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000016308","volume":"9","author":"B Wagenknecht","year":"1999","unstructured":"Wagenknecht B, Hermisson M, Eitel K, Weller M. Proteasome inhibitors induce p53\/p21-independent apoptosis in human glioma cells. Cell Physiol Biochem. 1999;9:117\u201325. https:\/\/doi.org\/10.1159\/000016308.","journal-title":"Cell Physiol Biochem"},{"key":"739_CR62","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1007\/s10637-012-9804-z","volume":"30","author":"A Zanotto-Filho","year":"2012","unstructured":"Zanotto-Filho A, Braganhol E, Battastini AM, Moreira JC. Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through Inhibition of PI3K\/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1\/2 signaling. Invest New Drugs. 2012;30:2252\u201362. https:\/\/doi.org\/10.1007\/s10637-012-9804-z.","journal-title":"Invest New Drugs"},{"key":"739_CR63","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1158\/1078-0432.CCR-11-0075.\/60","volume":"17","author":"T Unterkircher","year":"2011","unstructured":"Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, et al. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res. 2011;17:4019\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0075.\/60.","journal-title":"Clin Cancer Res"},{"key":"739_CR64","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1158\/1078-0432.CCR-07-0251","volume":"13","author":"R Koschny","year":"2007","unstructured":"Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, et al. Bortezomib sensitizes primary human Astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2007;13:3403\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0251.","journal-title":"Clin Cancer Res"},{"key":"739_CR65","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40880-019-0424-2","volume":"39","author":"JH Tang","year":"2019","unstructured":"Tang JH, Yang L, Chen JX, Li QR, Zhu LR, Xu QF, et al. Bortezomib inhibits growth and sensitizes glioma to Temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. Cancer Commun (Lond). 2019;39:81. https:\/\/doi.org\/10.1186\/s40880-019-0424-2.","journal-title":"Cancer Commun (Lond)"},{"key":"739_CR66","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3892\/or.2015.3875","volume":"33","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zhu X, Hou K, Zhao J, Han Z, Zhang X. Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis. Oncol Rep. 2015;33:2277\u201384. https:\/\/doi.org\/10.3892\/or.2015.3875.","journal-title":"Oncol Rep"},{"key":"739_CR67","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3171\/2013.7.JNS1323","volume":"119","author":"DA Bota","year":"2013","unstructured":"Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS. Proteasome Inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells\u2019 VEGF production and angiogenesis. J Neurosurg. 2013;119:1415\u201323. https:\/\/doi.org\/10.3171\/2013.7.JNS1323.","journal-title":"J Neurosurg"},{"key":"739_CR68","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41416-019-0551-1","volume":"121","author":"MA Rahman","year":"2019","unstructured":"Rahman MA, Gras Navarro A, Brekke J, Engelsen A, Bindesb\u00f8ll C, Sarowar S, et al. Bortezomib administered prior to Temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. Br J Cancer. 2019;121:545\u201355. https:\/\/doi.org\/10.1038\/s41416-019-0551-1.","journal-title":"Br J Cancer"},{"key":"739_CR69","first-page":"1283","volume":"20","author":"M Labussiere","year":"2008","unstructured":"Labussiere M, Pinel S, Delfortrie S, Plenat F, Chastagner P. Proteasome Inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts. Oncol Rep. 2008;20:1283\u20137.","journal-title":"Oncol Rep"},{"key":"739_CR70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12032-016-0767-3","volume":"33","author":"Z Areeb","year":"2016","unstructured":"Areeb Z, Stylli SS, Ware TM, Harris NC, Shukla L, Shayan R, et al. Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist Carfilzomib. Med Oncol. 2016;33:53. https:\/\/doi.org\/10.1007\/s12032-016-0767-3.","journal-title":"Med Oncol"},{"key":"739_CR71","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1021\/acs.molpharmaceut.8b00270","volume":"15","author":"M Zhang","year":"2018","unstructured":"Zhang M, Lu L, Ying M, Ruan H, Wang X, Wang H, et al. Enhanced glioblastoma targeting ability of Carfilzomib enabled by a DA7R-Modified lipid nanodisk. Mol Pharm. 2018;15:2437\u201347. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00270.","journal-title":"Mol Pharm"},{"key":"739_CR72","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.4161\/auto.22185","volume":"8","author":"Y Zang","year":"2012","unstructured":"Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, et al. The next generation proteasome inhibitors Carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012;8:1873\u20134. https:\/\/doi.org\/10.4161\/auto.22185.","journal-title":"Autophagy"},{"key":"739_CR73","doi-asserted-by":"publisher","unstructured":"Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E et al. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys. 2018;100:1195\u20131203. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.001. Erratum in: Int J Radiat Oncol Biol Phys. 2019;103:1289. doi:10.1016\/j.ijrobp.2019.01.071.","DOI":"10.1016\/j.ijrobp.2018.01.001"},{"key":"739_CR74","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/iid3.315","volume":"8","author":"MA Rahman","year":"2020","unstructured":"Rahman MA, Brekke J, Arnesen V, Hannisdal MH, Navarro AG, Waha A, et al. Sequential bortezomib and Temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. Immun Inflamm Dis. 2020;8:342\u201359. https:\/\/doi.org\/10.1002\/iid3.315.","journal-title":"Immun Inflamm Dis"},{"key":"739_CR75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11060-010-0143-7","volume":"100","author":"S Phuphanich","year":"2010","unstructured":"Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, Mikkelsen T, et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol. 2010;100:95\u2013103. https:\/\/doi.org\/10.1007\/s11060-010-0143-7.","journal-title":"J Neurooncol"},{"key":"739_CR76","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/mco.2020.2114","volume":"13","author":"J Quillin","year":"2020","unstructured":"Quillin J, Patel R, Herzberg E, Alton D, Bikzhanova G, Geisler L, et al. A phase 0 analysis of Ixazomib in patients with glioblastoma. Mol Clin Oncol. 2020;13:43. https:\/\/doi.org\/10.3892\/mco.2020.2114.","journal-title":"Mol Clin Oncol"},{"key":"739_CR77","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ijrobp.2008.08.050","volume":"74","author":"GJ Kubicek","year":"2009","unstructured":"Kubicek GJ, Werner-Wasik M, Machtay M, Mallon G, Myers T, Ramirez M, et al. Phase I trial using proteasome inhibitor bortezomib and concurrent Temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys. 2009;74:433\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.08.050.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"739_CR78","doi-asserted-by":"publisher","first-page":"e29168","DOI":"10.1002\/pbc.29168","volume":"68","author":"CM Hoerig","year":"2021","unstructured":"Hoerig CM, Plant-Fox AS, Pulley MD, Di K, Bota DA. Exploring the role and clinical implications of proteasome Inhibition in Medulloblastoma. Pediatr Blood Cancer. 2021;68:e29168. https:\/\/doi.org\/10.1002\/pbc.29168.","journal-title":"Pediatr Blood Cancer"},{"key":"739_CR79","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol. 2018;20:184\u201391. https:\/\/doi.org\/10.1093\/neuonc\/nox175.","journal-title":"Neuro Oncol"},{"key":"739_CR80","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/neuonc\/nov299","volume":"18","author":"K Di","year":"2016","unstructured":"Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ, Desjardins A, Trikha M, Bota DA, et al. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro Oncol. 2016;18:840\u20138. https:\/\/doi.org\/10.1093\/neuonc\/nov299.","journal-title":"Neuro Oncol"},{"key":"739_CR81","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/md8040835","volume":"8","author":"BC Potts","year":"2010","unstructured":"Potts BC, Lam KS. Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides. Mar Drugs. 2010;8:835\u201380. https:\/\/doi.org\/10.3390\/md8040835.","journal-title":"Mar Drugs"},{"key":"739_CR82","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/anie.200390115","volume":"42","author":"RH Feling","year":"2003","unstructured":"Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed Engl. 2003;42:355\u20137. https:\/\/doi.org\/10.1002\/anie.200390115.","journal-title":"Angew Chem Int Ed Engl"},{"key":"739_CR83","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.bmc.2008.10.075","volume":"17","author":"W Fenical","year":"2009","unstructured":"Fenical W, Jensen PR, Palladino MA, Lam KS, Lloyd GK, Potts BC. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem. 2009;17:2175\u201380. https:\/\/doi.org\/10.1016\/j.bmc.2008.10.075.","journal-title":"Bioorg Med Chem"},{"key":"739_CR84","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1021\/jm048995+","volume":"48","author":"VR Macherla","year":"2005","unstructured":"Macherla VR, Mitchell SS, Manam RR, Reed KA, Chao TH, Nicholson B, et al. Structure-activity relationship studies of salino-sporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem. 2005;48:3684\u20137. https:\/\/doi.org\/10.1021\/jm048995+.","journal-title":"J Med Chem"},{"key":"739_CR85","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/bjh.13780","volume":"171","author":"DS Das","year":"2015","unstructured":"Das DS, Ray A, Song Y, Richardson P, Trikha M, Chauhan D, et al. Synergistic anti-myeloma activity of the proteasome inhibitor Marizomib and the imid Immunomodulatory drug Pomalidomide. Br J Haematol. 2015;171:798\u2013812. https:\/\/doi.org\/10.1111\/bjh.13780.","journal-title":"Br J Haematol"},{"key":"739_CR86","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","volume":"8","author":"D Chauhan","year":"2005","unstructured":"Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell. 2005;8:407\u201319. https:\/\/doi.org\/10.1016\/j.ccr.2005.10.013.","journal-title":"Cancer Cell"},{"key":"739_CR87","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2006-03-013128","volume":"110","author":"CP Miller","year":"2007","unstructured":"Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 2007;110:267\u201377. https:\/\/doi.org\/10.1182\/blood-2006-03-013128.","journal-title":"Blood"},{"key":"739_CR88","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.leukres.2014.12.014","volume":"39","author":"FF Corrales-Medina","year":"2015","unstructured":"Corrales-Medina FF, Manton CA, Orlowski RZ, Chandra J. Efficacy of Panobinostat and Marizomib in acute myeloid leukemia and bortezomib-resistant models. Leuk Res. 2015;39:371\u20139. https:\/\/doi.org\/10.1016\/j.leukres.2014.12.014.","journal-title":"Leuk Res"},{"key":"739_CR89","doi-asserted-by":"publisher","first-page":"974573","DOI":"10.3389\/fonc.2022.974573","volume":"12","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Zhang S, Lin B, Wang Q, Nie X, Shi Y. Combined treatment of Marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo. Front Oncol. 2022;12:974573. https:\/\/doi.org\/10.3389\/fonc.2022.974573.","journal-title":"Front Oncol"},{"key":"739_CR90","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1158\/1078-0432.CCR-07-4506","volume":"14","author":"CM Sloss","year":"2008","unstructured":"Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, et al. Proteasome Inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res. 2008;14:5116\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4506.","journal-title":"Clin Cancer Res"},{"key":"739_CR91","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.7150\/thno.42705","volume":"10","author":"PV Raninga","year":"2020","unstructured":"Raninga PV, Lee A, Sinha D, Dong LF, Datta KK, Lu X, et al. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation Inhibition. Theranostics. 2020;10:5259\u201375. https:\/\/doi.org\/10.7150\/thno.42705.","journal-title":"Theranostics"},{"key":"739_CR92","doi-asserted-by":"publisher","first-page":"18409","DOI":"10.1038\/s41598-019-55003-2","volume":"9","author":"C Sourbier","year":"2019","unstructured":"Sourbier C, Ricketts CJ, Liao PJ, Matsumoto S, Wei D, Lang M, et al. Proteasome Inhibition disrupts the metabolism of fumarate hydratase-deficient tumors by downregulating p62 and c-Myc. Sci Rep. 2019;9:18409. https:\/\/doi.org\/10.1038\/s41598-019-55003-2.","journal-title":"Sci Rep"},{"key":"739_CR93","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41419-021-03927-x","volume":"12","author":"C Boccellato","year":"2021","unstructured":"Boccellato C, Kolbe E, Peters N, Juric V, Fullstone G, Verreault M, et al. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist. Cell Death Dis. 2021;12:647. https:\/\/doi.org\/10.1038\/s41419-021-03927-x.","journal-title":"Cell Death Dis"},{"key":"739_CR94","doi-asserted-by":"publisher","first-page":"vdab103","DOI":"10.1093\/noajnl\/vdab103","volume":"3","author":"C Verheul","year":"2021","unstructured":"Verheul C, Ntafoulis I, Kers TV, Hoogstrate Y, Mastroberardino PG, Barnhoorn S, et al. Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures. Neurooncol Adv. 2021;3:vdab103. https:\/\/doi.org\/10.1093\/noajnl\/vdab103.","journal-title":"Neurooncol Adv"},{"key":"739_CR95","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/neuonc\/noab264","volume":"24","author":"E Almstedt","year":"2022","unstructured":"Almstedt E, Ros\u00e9n E, Gloger M, Stockgard R, Hekmati N, Koltowska K, et al. Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts. Neuro Oncol. 2022;24:726\u201338. https:\/\/doi.org\/10.1093\/neuonc\/noab264.","journal-title":"Neuro Oncol"},{"key":"739_CR96","doi-asserted-by":"publisher","first-page":"eaaw0064","DOI":"10.1126\/scitranslmed.aaw0064","volume":"11","author":"GL Lin","year":"2019","unstructured":"Lin GL, Wilson KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med. 2019;11:eaaw0064. https:\/\/doi.org\/10.1126\/scitranslmed.aaw0064.","journal-title":"Sci Transl Med"},{"key":"739_CR97","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/1878-0261.13427","volume":"17","author":"EP Jane","year":"2023","unstructured":"Jane EP, Reslink MC, Gatesman TA, Halbert ME, Miller TA, Golbourn BJ, et al. Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas. Mol Oncol. 2023;17:1821\u201343. https:\/\/doi.org\/10.1002\/1878-0261.13427.","journal-title":"Mol Oncol"},{"key":"739_CR98","doi-asserted-by":"publisher","first-page":"18953","DOI":"10.1038\/srep18953","volume":"6","author":"C Manton","year":"2016","unstructured":"Manton C, Johnson B, Singh M, Bailey C, Bouchier-Hayes L, Chandra J. Induction of cell death by the novel proteasome inhibitor Marizomib in glioblastoma in vitro and in vivo. Sci Rep. 2016;6:18953. https:\/\/doi.org\/10.1038\/srep18953.","journal-title":"Sci Rep"},{"key":"739_CR99","doi-asserted-by":"publisher","first-page":"iv16","DOI":"10.1093\/neuonc\/noz167.070","volume":"21","author":"E Frisira","year":"2019","unstructured":"Frisira E, Rashid F, Michod D, Niklison Chirou MV. NPI-0052 and gamma-radiation induce a synergistic apoptotic effect in the most aggressive Medulloblastoma subgroup. Neuro Oncol. 2019;21:iv16. https:\/\/doi.org\/10.1093\/neuonc\/noz167.070.","journal-title":"Neuro Oncol"},{"key":"739_CR100","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s10637-011-9766-6","volume":"30","author":"M Millward","year":"2012","unstructured":"Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, et al. Phase 1 clinical trial of the novel proteasome inhibitor Marizomib with the histone deacetylase inhibitor Vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012;30:2303\u201317. https:\/\/doi.org\/10.1007\/s10637-011-9766-6.","journal-title":"Invest New Drugs"},{"key":"739_CR101","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/bjh.14113","volume":"174","author":"N Levin","year":"2016","unstructured":"Levin N, Spencer A, Harrison SJ, Chauhan D, Burrows FJ, Anderson KC, et al. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Br J Haematol. 2016;174:711\u201320. https:\/\/doi.org\/10.1111\/bjh.14113.","journal-title":"Br J Haematol"},{"key":"739_CR102","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1182\/blood.V114.22.431.431","volume":"114","author":"P Richardson","year":"2009","unstructured":"Richardson P, Hofmeister C, Jakubowiak A, Zimmerman TM, Spear MA, Palladino MA, et al. Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed\/Refractory multiple myeloma (MM). Blood. 2009;114:431. https:\/\/doi.org\/10.1182\/blood.V114.22.431.431.","journal-title":"Blood"},{"key":"739_CR103","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1182\/blood.V112.11.4939.4939","volume":"112","author":"PA Hamlin","year":"2008","unstructured":"Hamlin PA, Aghajanian C, Hong D, Younes A, Palladino MA, Longenecker AM, et al. First-in-Human phase 1 dose escalation study of NPI-0052, a novel proteasome inhibitor, in patients with lymphoma and solid tumor. Blood. 2008;112:4939. https:\/\/doi.org\/10.1182\/blood.V112.11.4939.4939.","journal-title":"Blood"},{"key":"739_CR104","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood.V112.11.4934.4934","volume":"112","author":"T Price","year":"2008","unstructured":"Price T, Padrik P, Townsend A, Mainwaring P, Catley L, Longenecker AM, et al. Clinical trial of NPI-0052 (2nd generation proteasome inhibitor) in patients having advanced malignancies with expanded RP2D cohorts in lymphoma and CLL. Blood. 2008;112:4934. https:\/\/doi.org\/10.1182\/blood.V112.11.4934.4934.","journal-title":"Blood"},{"key":"739_CR105","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jha2.72","volume":"1","author":"D Bazou","year":"2020","unstructured":"Bazou D, Le G, Boyle A, Blum A, O\u2019Gorman P, Marizomib. A novel therapeutic approach for the treatment of central nervous system myeloma. EJHaem. 2020;1:315\u20137. https:\/\/doi.org\/10.1002\/jha2.72.","journal-title":"EJHaem"},{"key":"739_CR106","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/bjh.14498","volume":"177","author":"A Badros","year":"2017","unstructured":"Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, et al. Marizomib for central nervous system-multiple myeloma. Br J Haematol. 2017;177:221\u20135. https:\/\/doi.org\/10.1111\/bjh.14498.","journal-title":"Br J Haematol"},{"key":"739_CR107","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1200\/JCO.2019.37.15_suppl.2021","volume":"37","author":"WP Mason","year":"2019","unstructured":"Mason WP, Kesari S, Stupp R, Gebremichael Aregawi D, Piccioni DE, Roth P, et al. Full enrollment results from an extended phase I, multicenter, open label study of Marizomib (MRZ) with Temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2019;37:2021. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2021.","journal-title":"J Clin Oncol"},{"key":"739_CR108","doi-asserted-by":"publisher","unstructured":"Bota DA, Di K, Keator DB, Bota RG, Hoffmann M, Dumitru CD et al. Human functional brain imaging data support preclinical and clinical evidence that marizomib crosses the blood-brain barrier (BBB) to inhibit proteasome activity in the brain. Cancer Res. 2019;79:Abstract nr 4733. https:\/\/doi.org\/10.1158\/1538-7445.AM2019-4733","DOI":"10.1158\/1538-7445.AM2019-4733"},{"key":"739_CR109","doi-asserted-by":"publisher","first-page":"vi16","DOI":"10.1093\/neuonc\/nox168.058","volume":"19","author":"D Bota","year":"2017","unstructured":"Bota D, Desjardins A, Mason W, Kesari S, Magge R, Winograd B, et al. Full enrollment results from the phase 1\/2, multicenter, open-label study of Marizomib (MRZ) +\/- bevacizumab (BEV) in recurrent WHO grade IV malignant glioma (glioblastoma, rGBM). Neuro Oncol. 2017;19:vi16. https:\/\/doi.org\/10.1093\/neuonc\/nox168.058.","journal-title":"Neuro Oncol"},{"key":"739_CR110","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1182\/blood-2015-12-686378","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Zimmerman TM, Hofmeister CC, Talpaz M, Chanan-Khan AA, Kaufman JL, et al. Phase 1 study of Marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 part 1. Blood. 2016;127:2693\u2013700. https:\/\/doi.org\/10.1182\/blood-2015-12-686378.","journal-title":"Blood"},{"key":"739_CR111","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","volume":"26","author":"P Roth","year":"2024","unstructured":"Roth P, Gorlia T, Reijneveld JC, de Vos F, Idbaih A, Frenel JS, et al. Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial. Neuro Oncol. 2024;26:1670\u201382. https:\/\/doi.org\/10.1093\/neuonc\/noae053.","journal-title":"Neuro Oncol"},{"key":"739_CR112","first-page":"ii74","volume":"21","author":"K Warren","year":"2019","unstructured":"Warren K, Shankarappa P, Peer C, Garcia RC, Monje-Deisseroth M, Figg WD, et al. Dipg-Optimizing clinical trial design: pharmacokinetics of Marizomib and Panobinostat in a non-human primate model. Neurooncology. 2019;21:ii74.","journal-title":"Neurooncology"},{"key":"739_CR113","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1365-2141.2010.08144.x","volume":"149","author":"AV Singh","year":"2010","unstructured":"Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol. 2010;149:550\u20139. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08144.x.","journal-title":"Br J Haematol"},{"key":"739_CR114","doi-asserted-by":"publisher","first-page":"1219291","DOI":"10.3389\/fphys.2023.1219291","volume":"14","author":"AG Bhargav","year":"2023","unstructured":"Bhargav AG, Domino JS, Alvarado AM, Tuchek CA, Akhavan D, Camarata PJ. Advances in computational and translational approaches for malignant glioma. Front Physiol. 2023;14:1219291. https:\/\/doi.org\/10.3389\/fphys.2023.1219291.","journal-title":"Front Physiol"},{"key":"739_CR115","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/neuonc\/noy027","volume":"20","author":"AM Vanderbeek","year":"2018","unstructured":"Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, et al. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018;20:1034\u201343. https:\/\/doi.org\/10.1093\/neuonc\/noy027.","journal-title":"Neuro Oncol"},{"key":"739_CR116","doi-asserted-by":"publisher","first-page":"102840","DOI":"10.1016\/j.jddst.2021.102840","volume":"66","author":"L Sui","year":"2021","unstructured":"Sui L, Xu G, Hao Y, Wang X, Tang K. Engineering of Marizomib loaded polymeric nanoparticles: in vivo safety profile and in vitro proliferation in hepatocellular carcinoma. J Drug Deliv Sci Technol. 2021;66:102840. https:\/\/doi.org\/10.1016\/j.jddst.2021.102840.","journal-title":"J Drug Deliv Sci Technol"},{"key":"739_CR117","doi-asserted-by":"publisher","first-page":"035403","DOI":"10.1088\/2053-1591\/ac5077","volume":"9","author":"J Xu","year":"2022","unstructured":"Xu J, Liao M, Chen Y, Chen L. Novel fabrication of marizomib-loaded chitosan-coated hydroxyapatite nanocarriers as a promising system for effective treatment of ovarian cancer. Mater Res Express. 2022;9:035403. https:\/\/doi.org\/10.1088\/2053-1591\/ac5077.","journal-title":"Mater Res Express"},{"key":"739_CR118","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.procbio.2023.09.005","volume":"134","author":"J Jing","year":"2023","unstructured":"Jing J, Meng Q, Hirad AH, Ramar M. Fabrication of marizomib-loaded zeolitic imidazolate framework-8@manganese dioxide for promising drug delivery system of glioma cancer cells. Process Biochem. 2023;134:54\u201362. https:\/\/doi.org\/10.1016\/j.procbio.2023.09.005.","journal-title":"Process Biochem"},{"issue":"10","key":"739_CR119","doi-asserted-by":"publisher","first-page":"e31402","DOI":"10.1016\/j.heliyon.2024.e31402","volume":"16","author":"RR Raju","year":"2024","unstructured":"Raju RR, AlSawaftah NM, Husseini GA. Modeling of brain tumors using in vitro, in vivo, and microfluidic models: A review of the current developments. Heliyon. 2024;16(10):e31402. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31402.","journal-title":"Heliyon"}],"updated-by":[{"DOI":"10.1007\/s43440-025-00755-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000}}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00739-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00739-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00739-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:03:45Z","timestamp":1758078225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00739-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00739-0","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s43440-025-00755-0","URL":"https:\/\/doi.org\/10.1007\/s43440-025-00755-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}